National Vision price to sales ratio EYE

Market value divided by revenue over the last twelve months, since 2018.

Today, Oct 23, 2026: 0.7×
9-year median: 1.3×
Against its 9-year history: 20th; percentile: 0 is its lowest day, 100 its highest
9-year range: 0.4× to 2.6×
Peer median: 3.4×

National Vision's price to sales ratio is 0.7× as of Oct 23, 2026.

That is below its 9-year median of 1.3×, lower than on 80% of days in the last 9 years.

Over that time it ranged from 0.4× in Sep 2024 to 2.6× in Nov 2021.

The median for 10 medical instruments and supplies stocks of a similar size is 3.4×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	0.7×	0.6×	1.2×
2025	1.2×	0.4×	1.2×
2024	0.4×	0.4×	0.9×
2023	0.8×	0.5×	1.7×
2022	1.5×	1.0×	1.7×
2021	1.9×	1.8×	2.6×
2020	2.3×	0.7×	2.4×
2019	1.6×	1.1×	1.8×
2018	1.5×	1.4×	2.4×

Against its peers

Companies in Medical - Instruments & Supplies nearest National Vision's size, closest first, today.

Company	Price to sales ratio
EYENational Vision	0.7×
CDRECadre	1.9×
BVSBioventus	2.2×
STAAStaar Surgical	3.3×
LMATLemaitre Vascular	7.4×
IRMDIradimed	12.7×
INSPInspire Medical Systems	2.3×
UFPTUFP Technologies	3.6×
ATRCAtriCure	5.3×
MOVMovado	1.0×
WRBYWarby Parker	3.5×
Peer median	3.4×

Where National Vision ranks

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on National Vision

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.